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Abstract
Introduction: Fatigue is prevalent in primary Sjögren’s syndrome (pSS), and contributes to the considerably
reduced health related quality of life in this disease. The symptom is included in proposed disease activity and
outcome measures for pSS. Several studies indicate that there is an inflammatory component of fatigue in pSS and
other chronic inflammatory rheumatic diseases. The purpose of this study was to investigate fatigue change in pSS
in a longitudinal study, and explore whether any clinical or laboratory variables at baseline, including serum
cytokines, were associated with a change in fatigue scores over time.
Methods: A clinical and laboratory investigation of 141 patients fulfilling the American-European consensus criteria
of pSS was undertaken in the period May 2004 to April 2005. Median time since diagnosis was 5.5 years.
Examinations included the fatigue questionnaires: fatigue severity scale (FSS), fatigue visual analogue scale (VAS),
functional assessment of chronic illness therapy - fatigue (FACIT-F) and medical outcome study short form-36 (SF-
36) vitality, which were repeated in a follow-up investigation in January and February 2010.
Results: A total of 122 patients (87%) responded at both time-points. Thirty-five percent of patients experienced a
clinically significant FSS increase. On the group level, fatigue measures did not change except that there was a
slight deterioration in SF-36 vitality score. High serum anti-Sjögren’s syndrome A antigen (anti-SSA) showed weak
associations with high baseline fatigue, and patients with increasing fatigue had lower baseline unstimulated
whole salivary volume. Weak associations between increasing fatigue and serum immunoglobulin G (IgG), and the
pro-inflammatory cytokine interleukin-17 (IL-17), were observed. Baseline sicca symptoms correlated with higher
fatigue both at baseline and with increasing fatigue over time. Linear regression analysis did not identify any
predictive ability of clinical or laboratory measures on fatigue change over time.
Conclusions: Fatigue remained mainly unchanged over time. Using multivariate models did not reveal any clinical
or laboratory predictors of fatigue change over time.
Introduction
Primary Sjögren’s syndrome (pSS) is a systemic rheu-
matic autoimmune disease targeting, in particular, exo-
crine glands, with eye and mouth dryness as classic
symptoms. Extraglandular manifestations include arthri-
tis, skin vasculitis and lymphoma [1]. Fatigue is a com-
mon complaint in pSS and other rheumatic disorders, as
well as in malignancies and several other chronic condi-
tions. Fatigue may be defined as “an overwhelming
sense of tiredness, lack of energy, and feeling of exhaus-
tion” [2]. Approximately 70% of pSS patients suffer from
substantial fatigue [3,4], compared with about 20% of
the normal population [5].
In rheumatic diseases, it is debated whether fatigue is
independently associated with disease activity. In pSS
the proposed disease activity measures Sjögren’s Syn-
drome Disease Activity Index (SSDAI) and Sjögren’s
Systemic Clinical Activity Index (SCAI) include fatigue
as well as other subjective health complaints, and fatigue
was included among a suggested core set of outcome
measures in pSS [6,7]. Possible direct or indirect causes
of fatigue in pSS that have been suggested include
chronic pain, hypothyroidism, and hypothalamus-pitui-
tary-adrenal axis disturbances [8,9]. Rituximab treatment
was associated with fatigue improvement in two small
double-blind, randomised studies, the most extensive of
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which included 20 pSS patients receiving rituximab and
10 receiving a placebo [10,11]. This treatment also
caused improved exocrine function. Another paper
reported a weak negative correlation between plasma
noradrenaline and a subscale of the Multidimensional
Fatigue Inventory in pSS, a finding which may reflect a
link between fatigue and autonomic nervous distur-
bances in this disease [12]. Recently, cerebrospinal IL-1
receptor antagonist (IL-1Ra) levels showed an associa-
tion with fatigue in a pSS study [13].
We have only identified one previous study investigat-
ing fatigue in pSS longitudinally. A Swedish follow-up
study assessed 47 patients with fatigue using a visual
analogue scale (VAS) and 29 patients with the vitality
domain of the Medical Outcome Study Short Form-36
(SF-36) at baseline and after five years [14]. Fatigue VAS
did not change significantly, while the mean SF-36 vital-
ity sub-score improved by 6.0 (P = 0.026). The study did
not report any change in baseline predictors of fatigue
over time. Only a few, low-sample studies have assessed
serum cytokines in relation to fatigue or health related
quality of life (HR-QOL) in pSS [3,15,16]. Serum levels
of interleukin (IL)-1b, IL-2, IL-6, IL-10 and tumour
necrosis factor (TNF) were found not to be associated
with multiple dimensions of fatigue in a cross-sectional
study with 60 pSS patients and 139 population based
controls [3].
The aims of this study were to investigate fatigue in
pSS patients in a follow-up study with a larger sample
size and to explore whether any clinical or laboratory
variables, including several cytokines at baseline, were
associated with change in fatigue scores over time.
Materials and methods
Patients and clinical examination
The Bergen pSS cohort at present comprises 141
patients fulfilling the American-European consensus cri-
teria [17], recruited from the out-patient registry of the
Department of Rheumatology, Haukeland University
Hospital. All patients underwent a new clinical and
laboratory investigation in the period May 2004 to April
2005. These investigations included Schirmer’s I test as
a measurement of the lacrimal function, and unstimu-
lated whole salivary excretion (UWS), in addition to
subjective assessments of dry eyes and dry mouth during
the past week on 100 mm VAS scales.
Laboratory analyses
Standard haematological and immunological tests were
carried out, including antinuclear antibodies (ANA),
anti-SSA and anti-Sjögren’s syndrome B antigen (anti-
SSB) and IgG. These laboratory tests were performed in
the routine hospital laboratory. ANA, anti-SSA and anti-
SSB were analysed by ELISA. Anti-SSA and -SSB
statuses were classified dichotomously; other serum and
blood laboratory values had continuous values. Lip
biopsy focus score was recorded from the medical files.
Serum cytokines were previously analysed at our labora-
tory [18]. The assay comprises analyses of 25 cytokines:
IL-1b, IL-1 receptor antagonist (IL-1Ra), IL-2, IL-2
receptor, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-10, IL-13, IL-15, IL-17, TNF, IL-12p40, interferon
(IFN)-g, IFN-a, granulocyte macrophage colony-stimulat-
ing factor (GM-CSF), monokine induced by IFN-g (MIG),
monocyte chemotactic protein-1 (MCP-1), IFN-g-
induced protein 10 kDa (IP-10), macrophage inflamma-
tory protein (MIP)-1a, MIP-1b, eotaxin and Regulated
upon Activation, Normal T-cell Expressed, and Secreted
(RANTES). Serum cytokine values below the lower limit
of detection were replaced with the lower limit values.
Evaluation of fatigue
Among fatigue instruments used in rheumatic disease
studies, including pSS, is the Fatigue Severity Scale (FSS),
Functional Assessment of Chronic Illness Therapy - Fati-
gue (FACIT-F) and different VAS variants. FSS assesses
functional issues during the preceding two weeks [19].
FACIT-F is a general fatigue measure with emphasis on
daily life function [20]. SF-36 assesses different health
aspects during the preceding four weeks [21]. The vitality
domain of SF-36 has been used as a proxy measure of
fatigue in several conditions. FSS and fatigue VAS are
positive scales in that higher values mean higher fatigue
levels, while FACIT-F and vitality have the opposite
direction. In the present study, Norwegian versions of
FSS, fatigue VAS, FACIT-F and SF-36 vitality were used.
The SF-36 mental health domain was also recorded and
included in the analyses to account for possible depres-
sion bias. Regarding fatigue VAS, patients were asked:
“How have you experienced fatigue (tretthet; that is,
“tiredness”) during last week?”, and the anchors were 0
mm = tiredness is no problem, and 100 mm = tiredness
is a big problem. The questionnaires were initially com-
pleted face-to-face in connection with the clinical investi-
gation in 2004 to 2005. At follow-up, postal
questionnaires were sent to the trial participants in Janu-
ary and February 2010. Three patients were deceased and
one had emigrated to an unknown location, thus 137
patients were sent questionnaires at this time. Patients
not responding also received a postal reminder and new
questionnaires. The study was approved by the Regional
Committee for Medical and Health Research Ethics, and
informed consent was obtained from all participants.
Statistics
The difference in fatigue measures between follow-up
and baseline was computed. To assess whether or not
fatigue changed over time, paired t-tests were applied.
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Fatigue was compared with the following clinical and
laboratory variables: serum cytokine concentrations,
CRP, serum IgG, ANA, anti-SSA, anti-SSB, blood sedi-
mentation rate, and Schirmer’s test, UWS, focus score,
VAS assessments of eye and mouth dryness, and pain.
Comparisons with baseline fatigue were performed
using Spearman’s rank coefficient (rho). Regarding
change in fatigue over time, these variables were com-
pared with continuous fatigue differences (using Spear-
man’s rho), and dichotomised differences (increased
fatigue or not, using the Mann-Whitney U test). Asso-
ciations between dichotomous variables were calculated
using Fisher’s exact test or McNemar’s test. Hierarchical
multiple linear regression was used to assess the ability
of clinical and laboratory control measures to predict
fatigue change over time, over and above any effect of
socio-demographic factors. Two-sided P-values were
computed, and P-values below 0.05 were considered sta-
tistically significant. Analyses were performed using
PASW Statistics 18.0 (SPSS Inc., Chicago, IL, USA) and
Prism 5 (GraphPad Software Inc., San Diego, CA, USA).
Power calculations were performed using PS 3.0 [22].
Results
Study sample and data quality
Median age at baseline was 57.0 years (range 24 to 74),
median time since onset of pSS symptoms was 13.0 years,
median time since diagnosis was 5.5 years, and 95% of the
patients were females. Non-responders at follow-up did
not significantly differ from responders in these respects.
Four patients used methotrexate, 25 used antimalarials, 9
used prednisolone, and 5 took other immunomodulatory
drugs. Baseline clinical and laboratory data were available
for all patients except for UWS, serum thyroxine and CRP
(N = 140), and focus score (N = 119).
One missing FACIT-F item at baseline, and six miss-
ing FACIT-F and four missing FSS items at follow-up,
were imputed by the method of using the personal
mean item score [23]. Also, eight fatigue or SF-36 items
at follow-up were originally filled in at two neighbouring
boxes, these were replaced with the mean value of the
two. After this, baseline fatigue data were complete for
the four fatigue measures, except a missing FSS score
for one of the 141 patients. Valid sample sizes for fati-
gue differences were 122 (FSS) or 121 (fatigue VAS,
FACIT-F and vitality).
Cross-sectional findings at baseline
Table 1 shows baseline correlations between the four
fatigue measures. Their absolute values varied between
0.47 and 0.75. This is a measure of convergent validity,
which may be accepted as very good vis-à-vis FACIT-F
(0.65 to 0.75), and good concerning the other measures.
Defined by an FSS-score of more than 4, 70.7% of
respondents reported high fatigue at baseline (Figure 1).
Median (mean) FSS score was 5.00 (4.78) (interquartile
range 3.67 to 6.22, SD 1.65).
Cross-sectional correlations with fatigue measures at
baseline are shown in Table 2. A clear positive correla-
tion between fatigue and pain was observed; moreover,
there was a significant positive correlation with mouth
dryness VAS. The SF-36 mental health domain (MH)
was included in the analyses to account for possible
depression bias. A low MH score was associated with
higher fatigue and mean MH was slightly lower in
patients with high fatigue defined by an FSS score > 4
(70.4 versus 76.7, P = 0.032). There were weak positive
correlations between fatigue and age, and Schirmer’s
test. ANA showed a slight negative correlation with
fatigue.
A positive serum anti-SSA was over-represented
among the high-fatigue patients (FSS > 4), with 68% of
these versus 46% of the low-fatigue patients having anti-
SSA (P = 0.023, odds ratio 2.42, 95% confidence interval
1.2 to 5.1). No cytokines in the 25-plex kit showed any
association at baseline versus continuous fatigue mea-
sures and cytokine concentrations in serum did not dif-
fer in patients with high fatigue (FSS > 4) compared
with patients having low fatigue. Dichotomising time
since symptom start using the median of 13 years as a
cut-off point did not reveal any difference in fatigue
measures. Patients with one year or less since diagnosis
(N = 17) had slightly higher median FSS than the other
participants (5.8 versus 5.0, P = 0.045). Regarding any
influence of anemia or hypothyroidism causing fatigue,
only one patient had a haemoglobin concentration
below 9 g/l, and all had normal thyroxine levels. Five
patients had elevated thyrotropin without concomitant
lowered thyroxine, their FSS did not differ from the
others (P = 0.93).
Longitudinal univariate associations
At follow-up, 122 participants (87%) returned the fatigue
questionnaires. Median follow-up time was 5.1 years
(range 4.8 to 5.8). The proportion with high fatigue
based on FSS did not change during the observation
Table 1 Pearson’s correlation coefficients between
fatigue measures at baseline
FACIT-F FSS Vitality
Fatigue VAS -0.65 0.47 -0.57
FACIT-F -0.67 0.75
FSS -0.51
N = 140 for FSS comparisons, otherwise 141. P < 0.001 for all comparisons.
Vitality and FACIT-F are negative scales, giving lower values with increasing
fatigue. VAS, visual analogue scale; FACIT-F, Functional Assessment of Chronic
Illness Therapy - Fatigue; FSS, Fatigue Severity Scale; vitality, short form-36
vitality domain.
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period (Figure 1). Using a minimal clinically important
difference (MCID) for FSS of 0.6 [24], 35% of patients
showed an FSS increase greater than this value. Floor-
ceiling effects can potentially cause skewed results, if
many patients have minimum or maximum scores so
that calculated differences are curtailed. Twelve (9.9%)
of the patients in the longitudinal analyses had the max-
imum FSS score of seven at baseline. Thirteen (10.7%)
patients reached maximum FSS at follow-up, seven of
these (5.7%) also had maximum FSS score at baseline.
Furthermore, two and three patients had the lowest FSS
score of one at baseline and follow-up, respectively.
Regarding fatigue VAS and vitality, the frequency of
minimum or maximum values varied from zero to four
patients at either time point. FACIT-F data did not
show floor-ceiling effects.
The difference in fatigue measures over time is illu-
strated in Figure 2, and the differences with standard
deviations are given in the figure legend. Mean vitality
showed a small but statistically significant worsening
from 37.4 to 34.4 (P = 0.045, mean difference -3.00, 95%
CI -5.92, -0.07). FSS, fatigue VAS and FACIT-F mean
differences were contradictory regarding the direction of
change, and their differences did not significantly devi-
ate from zero.
Baseline clinical and laboratory data showed no sig-
nificant correlation coefficients versus fatigue change
over time, except FSS difference versus mouth dryness
VAS (rho = 0.21, P = 0.02). Baseline MH showed no
association with fatigue change over time. Dichotomis-
ing fatigue change into presence or absence of
increased fatigue, showed several weak associations,
though with relatively high P-values when the high
number of comparisons is considered: baseline eye
dryness VAS (P = 0.033) and mouth dryness VAS (P =
0.020) were associated with increasing FSS. Also, base-
line UWS was somewhat higher in patients with FSS
increase (P = 0.02), and IgG showed a slight associa-
tion with decreasing vitality (P = 0.029). ANA showed
a weak positive correlation with vitality decrease (P =
0.034), contradictory to the cross-sectional findings.
Serum Il-17 (versus FSS increase, P = 0.020) and
RANTES (versus vitality decrease, P = 0.047) were
slightly higher among patients with increasing fatigue.
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Figure 1 Frequency of high fatigue. Percentage of patients with high fatigue level, N = 122. A high fatigue level defined as mean fatigue
severity scale (FSS) score > 4 was experienced by 70.7% at baseline and 72.1% at follow-up (P = 0.86, McNemar’s test). Using an FSS value of 5
as cut-off, the frequencies were 47.9% and 57.4%, respectively (P = 0.08, McNemar’s test).
Table 2 Cross-sectional fatigue measures, significant
correlations at baseline.
Correlating Spearman’s rho
covariates FSS Fatigue VAS FACIT-F Vitality
Age 0.20*
Mouth dryness VAS 0.31** -0.20* -0.20*
Pain VAS 0.32** 0.25** -0.48** -0.31**
Schirmer’s test 0.18*
ANA -0.19*
Mental health -0.19* 0.32** 0.24**
N was 140 or 141 for the different comparisons. FACIT-F, vitality and mental
health are negative scales (higher number means better health). *: P < 0.05;
**: P < 0.01. Abbreviations: see Table 1.
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CRP (P = 0.040) and IL-1b (P = 0.050) were lower in
patients with increasing fatigue.
Multivariate analysis
Hierarchical multiple linear regression was used to
assess the ability of baseline clinical and laboratory con-
trol measures to predict fatigue change over time
(Tables 3 and 4). Age, gender and education level were
entered at Step 1 (education level had values from 1 =
elementary school to 5 = university), Schirmer’s test and
UWS at Step 2, and focus score, anti-SSA/SSB, IgG and
the SF-36 MH subscore at Step 3. The dependent vari-
able was change in fatigue, and the model was repeated
for all fatigue measures (change in FSS, FACIT-F, fati-
gue VAS and vitality). Step 1 (socio-demographic fac-
tors) predicted change in vitality, but no other partial
model, and no final model, showed any significant pre-
diction (Tables 3 and 4). The analysis was also per-
formed with baseline mouth dryness, eye dryness and
pain VAS added to Step 2, with unaltered results.
-10 -5 0 5 10
Vitality
FACIT-F
Fatigue VAS
FSS
Figure 2 Change in fatigue over time. Errorbars showing 95% confidence intervals for the change in four different fatigue measures over time.
N = 122 for FSS, otherwise 121. The vertical line (zero) represents fatigue measures at baseline. FSS and FACIT-F data were normalised to a 0 to
100 scale, corresponding to fatigue VAS and vitality data. Mean change values (and standard deviations) without normalising were: FSS, 0.15
(0.12); fatigue VAS, -1.62 (2.20); FACIT-F, 0.78 (0.76); and vitality, -3.00 (1.48). Vitality (low values representing high fatigue) showed a statistically
but not clinically significant decrease over time. The tendencies in the other measures were increasing fatigue by FSS and decreasing fatigue by
VAS and FACIT-F. See Table 1 legend for definitions.
Table 3 Hierarchical multiple linear regression.
FSS difference FACIT-F difference VAS difference Vitality difference
Beta P Beta P Beta P Beta P
Age -0.10 0.42 -0.12 0.31 -0.11 0.37 -0.08 0.54
Education 0.04 0.69 -0.07 0.55 0.05 0.68 -0.19 0.08
Gender 0.03 0.79 -0.19 0.08 0.02 0.83 -0.08 0.50
Schirmer -0.06 0.60 -0.10 0.37 0.07 0.55 -0.04 0.74
UWS -0.05 0.65 -0.07 0.54 0.00 0.97 -0.08 0.47
Focus score 0.01 0.90 0.07 0.57 0.05 0.69 0.08 0.48
Anti-SSA -0.11 0.44 -0.06 0.68 -0.02 0.90 0.00 0.99
Anti-SSB -0.17 0.19 0.12 0.36 -0.13 0.34 0.10 0.46
IgG 0.09 0.46 0.00 0.98 -0.07 0.55 -0.09 0.45
Mental health -0.03 0.81 0.03 0.78 0.02 0.86 -0.07 0.52
ANA 0.00 0.98 -0.01 0.93 0.06 0.70 -0.14 0.37
Standardised coefficients (beta) and p-values, one regression model for each fatigue measure. The difference of each fatigue measure is the dependent variable.
N = 103 for focus score data among the 122 follow-up patients, other variables had larger samples. The P-values for each model were 0.88, 0.66, 0.96 and 0.82,
respectively. ANA, antinuclear antibodies; UWS, unstimulated whole saliva. FSS, VAS, FACIT-F, vitality, see Table 1 legend.
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Discussion
In 122 pSS patients, fatigue measured by FSS, FACIT-F,
vitality and fatigue VAS showed no significant change
during a mean follow-up time of 5.2 years, except a
weak vitality worsening. The observed vitality worsening
of 3.0 is not clinically significant according to a pro-
posed MCID for vitality in systemic lupus erythematosus
(SLE) of 10.7 [24]. Lack of association between time
since symptom start and fatigue measures also supports
a negative conclusion. Thirty-five percent of patients
showed clinically significant deterioration, when mea-
sured by FSS increase greater than a proposed MCID of
0.6. FSS was higher, and not lower, in patients with the
shortest time since diagnosis, which indicates that the
fatigue due to pSS arises before diagnosis. In addition,
there were no baseline clinical or laboratory predictors
for fatigue change over time.
The increased fatigue in pSS and other rheumatic dis-
eases may be comprised of an inflammatory and a psy-
chosocial part [25]. Whether fatigue measures and
assessment of other subjective complaints should be
included in pSS disease activity and outcome measures
is being discussed [7]. The main symptom change prob-
ably occurs early in the disease, and substantial diagnos-
tic delay is rather the rule in pSS. In one study, mean
time from first medical consultation to final diagnosis
was nine years [26]; in our material, mean (median)
time from symptom start to diagnosis was 6.0 (8.2)
years.
It has also been difficult to show any reduction in exo-
crine function or HR-QOL over time [14,27]. Further, in
sicca symptoms without inflammatory disease features,
fatigue may be as prevalent as in pSS [28,29], which
probably reflects a common psychosocial contribution
to fatigue. Fatigue in rheumatic disease may largely be
an unspecific sensation due to disease chronicity and
damage. Fatigue measures do not distinguish between
the effects of reversible inflammation and organ damage.
In pSS, reduced exocrine function can strongly influence
quality of life, and fatigue may be an unspecific part of
this. Rituximab treatment was associated with fatigue
improvement in two small double-blind, randomised
studies [10,11]. This points to an attributable inflamma-
tory component in fatigue in pSS, although such a con-
clusion could also be biased by improved exocrine
function unspecifically causing less fatigue. In the pre-
sent study, patients with one year or less since diagnosis
had slightly higher median FSS than the other partici-
pants. This points to a plausible connection between
higher disease activity in “early” pSS and, thus, higher
fatigue, a hypothesis which should be explored in
further studies using validated pSS disease activity
measures.
Other researchers have found an association between
depression and fatigue in pSS [4,12,30]. Depression
does, however, not seem to be the primary cause of fati-
gue in this disease [4]. The SF-36 MH subscale, which
mainly comprises depressive symptoms, showed lower
values (more symptoms) in patients with high fatigue
(FSS > 4). However, a fatigue change bias by mental
symptoms as reflected in MH was not evident in the
multivariate analyses.
In the cross-sectional analyses, a positive anti-SSA was
over-represented among the high-fatigue patients (FSS >
4), with an odds ratio of 2.42. We also report a number
of other minor findings, some of which may be inciden-
tal due to the high number of statistical comparisons.
Regarding IgG, anti-SSA, and the pro-inflammatory
cytokine IL-17, further studies should explore whether
the findings can be replicated in pSS patient serum.
Also, cytokine concentrations could preferably be ana-
lysed in cerebrospinal fluid, though this does not neces-
sarily address neurologic changes because other
mechanisms, for example, autonomic dysfunction, may
be responsible for neurologic dysfunction in fatigue.
All in all, this study found mainly unchanged fatigue
over time in pSS, as in the previous smaller study [14].
In addition, there was no reliable association with base-
line salivary or lacrimal function, autoantibodies or
focus score. The present work employed a higher sam-
ple size giving better power. Serum cytokines in pSS
have not been investigated earlier in relation to change
in fatigue over time, and this study includes a larger
number of cytokines to explore possible links to the bio-
logic correlate of fatigue.
Our study has some limitations. The limited sample
size may have influenced our findings. Given the
observed dispersion and a power of 80%, our data
would permit the detection of a true mean difference in
FSS, fatigue VAS and FACIT-F of 0.36, 6.27, and 8.30,
respectively. Another issue is floor-ceiling effects, and 7
of the 122 patients had the maximum FSS score both at
baseline and follow-up, possibly masking any change
over time. By hypothetically changing these seven
Table 4 Hierarchical multiple linear regression.
Independent variables Change in fatigue measure
FSS Fatigue
VAS
FACIT-
F
Vitality
Age, Gender, Highest education 0.014 0.021 0.051 0.094*
Schirmer, UWS 0.004 0.007 0.024 0.003
Focus score, anti-SSA, anti-SSB,
IgG, MH
0.058 0.071 0.012 0.025
The table shows R square change values for each group of independent
variables added in the regression model. R square change values signify the
proportion of the total model variance that is explained by adding each of
the variable groups. UWS, unstimulated whole saliva; MH, SF-36 mental health
domain. Abbreviations, see Table 1 legend. * P = 0.047.
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baseline FSS values to the lowest value of 1, the FSS dif-
ference would change from 0.15 to 0.50 (P = 0.006),
which is still below the proposed MCID of 0.6 for FSS
[24]. Baseline fatigue data were collected by question-
naires completed face-to-face. At follow-up, postal ques-
tionnaires were used, and this may have influenced or
skewed the follow-up fatigue data.
Conclusions
In 122 pSS patients, fatigue measured by FSS, FACIT-F,
SF-36 vitality and fatigue VAS showed no significant
change during a mean follow-up time of 5.2 years,
except a weak but not clinically significant worsening in
vitality score (P = 0.045). A total of 35% of patients
experienced a clinically significant FSS increase. Multiple
regression models showed no predictive ability of
important clinical and laboratory variables on change in
fatigue. In univariate analyses, high serum anti-SSA
showed weak associations with high baseline fatigue,
and patients with increasing fatigue had lower baseline
UWS. Baseline sicca symptoms correlated with higher
fatigue both at baseline and with increasing fatigue over
time. Weak associations between increasing fatigue and
serum IgG, and the pro-inflammatory cytokine IL-17,
were observed. Although not consistently associated
both at baseline and follow-up, further studies should
explore whether these associations with laboratory vari-
ables can be replicated in pSS patient serum, and cyto-
kine concentrations could preferably be analysed in
cerebrospinal fluid.
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